BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 27325643)

  • 21. Metastatic Colorectal Cancer Rewrites Metabolic Program Through a Glut3-YAP-dependent Signaling Circuit.
    Kuo CC; Ling HH; Chiang MC; Chung CH; Lee WY; Chu CY; Wu YC; Chen CH; Lai YW; Tsai IL; Cheng CH; Lin CW
    Theranostics; 2019; 9(9):2526-2540. PubMed ID: 31131051
    [No Abstract]   [Full Text] [Related]  

  • 22. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
    Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
    J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
    Hao Y; Chun A; Cheung K; Rashidi B; Yang X
    J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer.
    Zhang D; Zhao L; Shen Q; Lv Q; Jin M; Ma H; Nie X; Zheng X; Huang S; Zhou P; Wu G; Zhang T
    Int J Cancer; 2017 May; 140(10):2298-2309. PubMed ID: 28213952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells.
    Wang L; Shi S; Guo Z; Zhang X; Han S; Yang A; Wen W; Zhu Q
    PLoS One; 2013; 8(6):e65539. PubMed ID: 23762387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
    Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
    Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer.
    Wang G; Gu J; Gao Y
    Tumour Biol; 2016 Oct; 37(10):13983-13993. PubMed ID: 27492459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.
    Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF
    Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker.
    Chen D; Sun Y; Wei Y; Zhang P; Rezaeian AH; Teruya-Feldstein J; Gupta S; Liang H; Lin HK; Hung MC; Ma L
    Nat Med; 2012 Oct; 18(10):1511-7. PubMed ID: 23001183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
    Moleirinho S; Chang N; Sims AH; Tilston-Lünel AM; Angus L; Steele A; Boswell V; Barnett SC; Ormandy C; Faratian D; Gunn-Moore FJ; Reynolds PA
    Oncogene; 2013 Apr; 32(14):1821-30. PubMed ID: 22614006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High levels of SIRT1 expression enhance tumorigenesis and associate with a poor prognosis of colorectal carcinoma patients.
    Chen X; Sun K; Jiao S; Cai N; Zhao X; Zou H; Xie Y; Wang Z; Zhong M; Wei L
    Sci Rep; 2014 Dec; 4():7481. PubMed ID: 25500546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis.
    Fang L; Teng H; Wang Y; Liao G; Weng L; Li Y; Wang X; Jin J; Jiao C; Chen L; Peng X; Chen J; Yang Y; Fang H; Han D; Li C; Jin X; Zhang S; Liu Z; Liu M; Wei Q; Liao L; Ge X; Zhao B; Zhou D; Qin HL; Zhou J; Wang P
    Cancer Cell; 2018 Jul; 34(1):103-118.e9. PubMed ID: 30008322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.
    Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
    Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
    J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma.
    Dong Q; Fu L; Zhao Y; Xie C; Li Q; Wang E
    Oncotarget; 2017 Feb; 8(9):15689-15703. PubMed ID: 28152516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer.
    Shen J; Cao B; Wang Y; Ma C; Zeng Z; Liu L; Li X; Tao D; Gong J; Xie D
    J Exp Clin Cancer Res; 2018 Jul; 37(1):175. PubMed ID: 30055645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
    Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A feed forward loop enforces YAP/TAZ signaling during tumorigenesis.
    Gill MK; Christova T; Zhang YY; Gregorieff A; Zhang L; Narimatsu M; Song S; Xiong S; Couzens AL; Tong J; Krieger JR; Moran MF; Zlotta AR; van der Kwast TH; Gingras AC; Sicheri F; Wrana JL; Attisano L
    Nat Commun; 2018 Aug; 9(1):3510. PubMed ID: 30158528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
    Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
    Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.